Q3 2023 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2023-11-14 · accession 0001104659-23-118157
$17.35B
Reported value
101
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 81181C104 | — | Seagen Inc. | $9.45B | 54.5% | 44,554,162 | Common | SOLE |
| 07725L102 | ONC | BeiGene, Ltd. | $2.10B | 12.1% | 11,668,897 | Common | SOLE |
| 45337C102 | INCY | Incyte Corporation | $2.09B | 12.0% | 36,178,566 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $893.3M | 5.15% | 42,864,612 | Common | SOLE |
| 09061G101 | BMRN | BioMarin Pharmaceutical Inc. | $337.1M | 1.94% | 3,810,248 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $225.6M | 1.30% | 1,545,113 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $153.7M | 0.89% | 6,702,349 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $138.7M | 0.80% | 11,877,171 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $130.8M | 0.75% | 2,520,731 | Common | SOLE |
| 46185LAD5 | — | Invitae Corporation | $130.4M | 0.75% | 300,000,000 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $119.8M | 0.69% | 2,368,378 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $95.5M | 0.55% | 20,763,323 | Common | SOLE |
| 09058V103 | BCRX | BioCryst Pharmaceuticals, Inc. | $90.0M | 0.52% | 12,710,818 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $78.3M | 0.45% | 4,578,280 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $76.9M | 0.44% | 4,865,819 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $74.5M | 0.43% | 2,691,493 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $74.3M | 0.43% | 151,215 | Common | SOLE |
| 85205L107 | SWTXUSD | SpringWorks Therapeutics, Inc. | $69.4M | 0.40% | 2,999,846 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $66.0M | 0.38% | 4,750,400 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $65.3M | 0.38% | 5,640,816 | Common | SOLE |
| 60468T105 | MRTXEUR | Mirati Therapeutics, Inc. | $61.4M | 0.35% | 1,409,784 | Common | SOLE |
| G5269C101 | — | Kiniksa Pharmaceuticals, Ltd. | $48.8M | 0.28% | 2,809,577 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc. | $48.7M | 0.28% | 1,366,547 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $47.3M | 0.27% | 2,292,003 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $31.3M | 0.18% | 10,123,824 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $31.2M | 0.18% | 17,310,490 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $30.5M | 0.18% | 3,882,125 | Common | SOLE |
| 09077A106 | BMEA | Biomea Fusion, Inc. | $29.0M | 0.17% | 2,108,949 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $28.7M | 0.17% | 1,062,123 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $27.9M | 0.16% | 17,239,501 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $26.6M | 0.15% | 1,963,479 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences, Inc. | $26.4M | 0.15% | 3,157,764 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $25.7M | 0.15% | 751,639 | Common | SOLE |
| 12674W109 | CABA | Cabaletta Bio, Inc. | $24.3M | 0.14% | 1,594,000 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $23.5M | 0.14% | 4,916,095 | Common | SOLE |
| 23306J101 | — | DBV Technologies S.A. | $19.9M | 0.11% | 14,614,264 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc. | $19.7M | 0.11% | 169,934 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc. | $18.8M | 0.11% | 1,416,530 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $17.0M | 0.10% | 843,814 | Common | SOLE |
| 45258J102 | IMVT | Immunovant, Inc. | $16.3M | 0.09% | 425,009 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences, Inc. | $12.6M | 0.07% | 1,292,966 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $12.3M | 0.07% | 1,000,000 | Common | SOLE |
| 74168J101 | PRME | Prime Medicine, Inc. | $9.8M | 0.06% | 1,028,466 | Common | SOLE |
| 901384107 | TSVT* | 2seventy bio, Inc. | $9.8M | 0.06% | 2,497,526 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $9.8M | 0.06% | 1,160,117 | Common | SOLE |
| 69404D108 | PACB | Pacific Biosciences of California, Inc. | $9.4M | 0.05% | 1,127,782 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $8.7M | 0.05% | 343,000 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $8.6M | 0.05% | 10,969,282 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics, Inc. | $8.4M | 0.05% | 750,000 | Common | SOLE |
| 427746102 | HRTX | Heron Therapeutics, Inc. | $8.4M | 0.05% | 8,131,678 | Common | SOLE |
| 04335A105 | ARVN | Arvinas, Inc. | $8.1M | 0.05% | 413,481 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $7.9M | 0.05% | 2,504,756 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $7.7M | 0.04% | 2,000,000 | Common | SOLE |
| 09609G100 | — | bluebird bio, Inc. | $7.6M | 0.04% | 2,499,715 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals, Inc. | $7.6M | 0.04% | 2,006,451 | Common | SOLE |
| 786700104 | SGMT | Sagimet Biosciences Inc. | $7.2M | 0.04% | 815,359 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $7.1M | 0.04% | 2,784,792 | Common | SOLE |
| 374163103 | GERN | Geron Corporation | $6.5M | 0.04% | 3,061,224 | Common | SOLE |
| 04746L104 | — | Athira Pharma, Inc. | $6.4M | 0.04% | 3,153,807 | Common | SOLE |
| 014442107 | ALEC | Alector, Inc. | $6.3M | 0.04% | 964,851 | Common | SOLE |
| 46185LAH6 | — | Invitae Corporation | $6.2M | 0.04% | 9,274,000 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals, Inc. | $6.0M | 0.03% | 190,476 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $6.0M | 0.03% | 1,049,699 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc. | $5.9M | 0.03% | 3,140,473 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $5.9M | 0.03% | 1,485,915 | Common | SOLE |
| 43906K100 | HOOKGBP | HOOKIPA Pharma Inc. | $5.0M | 0.03% | 8,065,398 | Common | SOLE |
| 61775R105 | MORFUSD | Morphic Holding, Inc. | $4.9M | 0.03% | 215,800 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $4.9M | 0.03% | 535,478 | Common | SOLE |
| 64049K203 | — | Neoleukin Therapeutics, Inc. | $4.8M | 0.03% | 1,221,414 | Common | SOLE |
| 00032Q104 | WHWK | Aadi Bioscience, Inc. | $4.8M | 0.03% | 989,928 | Common | SOLE |
| 68386J208 | OPTEY | Opthea Limited | $4.7M | 0.03% | 2,690,891 | Common | SOLE |
| 632307104 | NTRA | Natera, Inc. | $4.4M | 0.03% | 100,000 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $3.5M | 0.02% | 1,500,000 | Common | SOLE |
| 74006W108 | — | Praxis Precision Medicines, Inc. | $3.2M | 0.02% | 1,879,915 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $3.1M | 0.02% | 1,557,630 | Common | SOLE |
| 87424L207 | TLIS | Talis Biomedical Corporation | $2.9M | 0.02% | 508,323 | Common | SOLE |
| 38406L103 | — | Gracell Biotechnologies Inc. | $2.9M | 0.02% | 1,000,000 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $2.8M | 0.02% | 1,515,342 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte, Inc. | $2.5M | 0.01% | 48,885 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $2.5M | 0.01% | 123,127 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO, Inc. | $2.4M | 0.01% | 266,613 | Common | SOLE |
| 00449L102 | 698 | Achilles Therapeutics plc | $2.3M | 0.01% | 2,557,149 | Common | SOLE |
| 15673T100 | IPSC | Century Therapeutics, Inc. | $2.3M | 0.01% | 1,149,340 | Common | SOLE |
| N01045108 | — | Affimed N.V. | $2.1M | 0.01% | 4,448,644 | Common | SOLE |
| 46489V104 | ISREUR | Perspective Therapeutics, Inc. | $2.1M | 0.01% | 7,639,703 | Common | SOLE |
| 45783C101 | — | Instil Bio, Inc. | $2.0M | 0.01% | 4,704,395 | Common | SOLE |
| 69353Y103 | PMVP | PMV Pharmaceuticals, Inc. | $2.0M | 0.01% | 322,024 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio, Inc. | $1.9M | 0.01% | 106,197 | Common | SOLE |
| 730541109 | — | POINT Biopharma Global Inc. | $1.7M | 0.01% | 249,968 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $1.6M | 0.01% | 150,346 | Common | SOLE |
| 52187K200 | CYPH | Leap Therapeutics, Inc. | $1.6M | 0.01% | 1,172,175 | Common | SOLE |
| 01626L105 | — | Aligos Therapeutics, Inc. | $1.6M | 0.01% | 2,076,400 | Common | SOLE |
| 59045L106 | — | Mersana Therapeutics, Inc. | $1.4M | 0.01% | 1,086,115 | Common | SOLE |
| 929033108 | — | Vor Biopharma Inc. | $1.3M | 0.01% | 633,848 | Common | SOLE |
| 46185L103 | NVTA1EUR | Invitae Corporation | $1.1M | 0.01% | 1,764,546 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences, Inc. | $1.1M | 0.01% | 166,347 | Common | SOLE |
| 04965G109 | BCELUSD | Atreca, Inc. | $922,050 | 0.01% | 3,532,760 | Common | SOLE |
| 37186H100 | — | Genetron Holdings Limited | $369,754 | 0.00% | 455,306 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $333,451 | 0.00% | 199,671 | Common | SOLE |
| 344174107 | FHTX | Foghorn Therapeutics Inc. | $225,135 | 0.00% | 45,027 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $34,250 | 0.00% | 833,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.